We previously reported that neuronal nitric oxide synthase (nNOS) is the predominant NOS in the intestine. Inducible NOS (iNOS), an enzyme involved in the inflammatory response, is regulated by cytokines via the transcriptional factor NF-B. We examined a new mechanism of intestinal iNOS regulation with respect to the role of nNOS and its effect on NF-B. Young Sprague-Dawley rats were treated for 4 days with 1) saline, 2) 7-nitroindazole (7-NI, specific nNOS inhibitor), 3) 7-NI ؉ pyrrolidine dithiocarbamate (PDTC, NF-B inhibitor), or 4) PDTC. Intestinal iNOS mRNA, NF-B activity, and the tissue content of the regulatory IB␣ were examined. We found that 7-NI-treated animals had higher intestinal NF-B (p50-p65) activity, lower IB␣ content, and increased intestinal iNOS mRNA, iNOS protein, and iNOS activity compared with controls. All of these changes were abolished when PDTC was given together with 7-NI. PDTC alone had no effect. 7-NI induces a delayed increase in intestinal myeloperoxidase activity (after elevation in NF-B and iNOS), which could be abrogated by PDTC. We conclude that in normal rat small intestine, nNOS suppresses the gene expression of iNOS through NF-B down-regulation and that nNOS suppression leads to IB␣ degradation, NF-B activation, and iNOS expression. 
Nitric oxide (NO), a molecule with diverse physiological functions, is produced in vivo through the conversion of L-arginine to L-citrulline by nitric oxide synthase (NOS). The family of NOS enzyme consists of 3 members: type I, neuronal NOS (nNOS), type II, inducible NOS (iNOS), and type III, endothelial NOS (eNOS) (reviewed in refs 1, 2). These isoforms, although structurally related, differ from each other in their genetic origin, anatomical distribution, ion dependence for activity, and pathophysiological functions (1) . nNOS and eNOS are constitutively present in many cells and tissues, whereas iNOS is usually not expressed except in the inflammatory state (2) . In the intestine, the constitutive NOS may have important physiological functions such as maintaining the blood flow (3, 4) and motility (5) . The function of iNOS in the gut is more complex. It is generally believed that iNOS is involved in the defense mechanism against bacteria (2) and may mediate the inflammatory response (2) when induced. We have previously reported that although all 3 types of NOS are constitutively present in rat small intestine, the predominant form (Ͼ90%) is nNOS (6, 7) . Unlike most organs where no iNOS is found in unstimulated conditions, normal intestine contains a low level of iNOS that is 'constitutively' expressed; both iNOS protein and iNOS activity can be detected, mostly in epithelial cells (8, 7) , although its contribution to the total tissue NOS activity is usually less than 5% (7) . The expression of iNOS in many cells and tissues can be rapidly up-regulated after challenge with bacterial lipopolysaccharide (LPS) and proinflammatory cytokines such as interleukin 1, tumor necrosis factor ␣ (TNF-␣), or interferon ␥ (IFN␥) (9) . This regulation is presumably via the activation of NF-B, a transcription factor involved in the regulation of many proinflammatory cytokines and enzymes (reviewed in ref 10) .
The transcription factor NF-B plays an important role in inflammation by regulating the transcription of proinflammatory cytokines (10) , adhesion molecules (10) , and proinflammatory enzymes such as iNOS (10) . NF-B is constitutively active at a low level in some cells but most of the NF-B is cytoplasmic, in an inactive state, and linked to a potent inhibitor, IB (10) . Upon stimulation by cytokines or reactive oxygen species, NF-B dissociates from its inhibitor and is translocated into the nucleus. There it binds specifically to the B sites and initiates the transcription (10) . NF-B consists of homo-or heterodimers of subunits p50, p52, p65, RelB, and c-Rel (10) . The essential role of NF-B in iNOS expression is suggested by the demonstration that deletion of the B binding sites in the promoter region of iNOS renders the gene unresponsive to cytokine stimulation (11) . Due to the potent proinflammatory role of iNOS, it is reasonable to assume that iNOS is under tight control and is kept suppressed under normal circumstances. However, its regulation in the physiological state is poorly understood. It has been shown that exogenously applied NO inhibits NF-B as well as expression of iNOS in human microglial cells (12) . In the present study, we examined the hypothesis that in normal intestine, nNOS (the predominant NOS) down-regulates iNOS and, conversely, nNOS inhibition induces iNOS expression. We investigated the mechanism of this regulation with respect to the role of transcription factor NF-B and its inhibitor, IB␣.
MATERIALS AND METHODS

Animal experiment
Young Sprague-Dawley rats (150 -180 g) were divided into 4 groups and given the following treatment: 1) saline (control), 2) 7-nitroindazole (7-NI, specific nNOS inhibitor (CalBiochem, San Diego, Calif., 100 mg/ml in DMSO), 25 mg/kg, twice daily, intraperitoneal (i.p.) (13), 3) 7-NI ϩ pyrroldine dithiocarbamate (PDTC, an inhibitor of NF-B activation; Sigma, St. Louis, Mo., 100 mg/ml in saline), 25 mg/kg, twice daily, i.p. (14) , and 4) PDTC only (25 mg/kg, twice daily, i.p.). (Since preliminary experiments showed that DMSO, the vehicle for 7-NI, has no effect on the parameters measured compared with saline controls, only the saline control group is presented.) Each animal was weighed at the time of injection (day 0) and killed.
At 1-4 day after the first drug injection, the animals were killed by an overdose of sodium pentobarbital and heart puncture. The procedure is in full compliance with the guidelines of the Institutional Animal Care and Use Committee. The small intestines were removed, rinsed with ice-cold saline containing dithiothreitol (DTT, 5.0 mM), minced with scissors, snap-frozen in liquid nitrogen, and stored in a Ϫ80°C freezer. Blood samples (0.5 ml/animal) were collected from some of the animals through a pyrogen-free catheter surgically implanted in the carotid artery and placed into sterilized, pyrogen-free centrifuge tubes (each containing 20 U heparin) before death. Plasma was then prepared from these blood samples by centrifugation at 15,000 ϫ g for 5 min and stored in a Ϫ80°C freezer.
Determination of intestinal nuclear NF-B-DNA binding activity
The nuclear protein was extracted from intestinal tissue following a published procedure (15) . In short, the frozen tissue sample was ground into fine powder with mortar/pestle in liquid nitrogen and suspended in a 'cushion buffer' [10 mM HEPES containing 0.6% Nonidet-40, 150 mM NaCl, 1.0 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), pH 7.9]. The suspension was then homogenized and centrifuged at 1000 g, 4°C, for 2 min to remove large tissue debris. Cell nuclei were harvested by centrifuging the supernatant at 5000 g, 4°C, for 5 min and nuclear protein was extracted with a hypertonic 'lysing buffer' [20 mM HEPES, containing 25% (v/v) glycerol, 420 mM NaCl, 1.2 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and leupeptin, aprotinin both at 0.5 g/ml], followed by centrifugation. The protein content of the nuclear extract was determined using a total protein quantification kit (Sigma). The samples were stored in a Ϫ80°C freezer before use.
The NF-B-DNA binding activity of the nuclear protein extract was determined by measuring its binding to the [ 32 P]-labeled consensus oligo-polypeptide using the polyacrylamide electrophoresis mobility shift assay (EMSA) as described (16) . Subunits forming the NF-B complex were identified by a supershift procedure using mAb against the p65 or p50 subunit of NF-B (Santa Cruz Biotechnology, Santa Cruz, Calif.), as described previously (16) .
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from intestinal tissue by homogenizing the samples in a RNA-extracting agent, STAT-60 (TEL-TEST, Friendswood, Tex.), together with chloroform treatment and isopropanol precipitation, following the manufacturer's instructions. The extracted RNA was reversely transcribed at 37°C by using random hexamer (pdN6) and Moloney murine leukemia virus reverse transcriptase (Gibco-BRL, Grand Island, N.Y.). cDNA was amplified by PCR with AmpliTaq DNA polymerase and specific primers flanking the corresponding gene segments. The sequence of primers and the PCR thermocycle profiles are as reported previously (17) . The PCR products were resolved by agarose gel electrophoresis and visualized by staining with SYBR Green-1 (Molecular Probe, Eugene, Oreg.). iNOS transcription was analyzed by semiquantitative RT-PCR. The fluorescence of the PCR products of iNOS and ␤-actin amplified from the same RT reaction was analyzed using a STORM-860 Phosphor-imager; the iNOS/ ␤-actin ratio was used as an index for the level of iNOS transcription for data analysis.
Assay of iNOS activity
The activity of iNOS was determined by a [ 14 C] L-arginine conversion method, as published (7) . The iNOS activity is defined as the difference between the EDTA containing reaction system and the reaction system containing both EDTA and nonspecific NOS inhibitor N G -monomethyl-Larginine (CalBiochem) at 50 mM. The protein content of the sample was determined using a Sigma total protein kit.
Detection of iNOS and IB␣ protein by immunoprecipitation and Western blotting
Intestinal tissue lysate was prepared (18) , and the protein concentration was determined. After precleaning with protein-A agarose, 1.0 ml tissue lysate (0.25 mg protein) was incubated with 30 l anti-NOS mAb M-19 (Santa Cruz Biotechnology) at 4°C with gentle shaking for 3 h, followed by incubation with excess (40 l) protein-A agarose beads for 2 h at 4°C. The bound immune complex was eluted with Laemmli sample buffer (Bio-Rad Laboratories, Hercules, Calif.) and boiling. After centrifugation, the supernatant was loaded on a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for electrophoresis resolution. For the detection of IB␣, tissue lysate/Laemmli buffer mixture was boiled and loaded for electrophoresis. The resolved protein was transferred to a nitrocellulose membrane, and the blot was detected with anti-iNOS mAb M-19 or anti-IB␣ mAb C-21 (Santa Cruz Biotechnology), horseradish peroxidase-labeled goat anti-rabbit IgG antibody, and visualized with an ECL system from Amersham.
Determination of intestinal myeloperoxidase activity and histological examination
Myeloperoxidase (MPO, a marker enzyme for neutrophils) assay was performed according to published methods (19) . Briefly, intestinal tissues were homogenized in 0.05 M potassium phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide and EDTA (5 mM), and sonicated. An aliquot was mixed with substrate (O-dianisidine HCl ϩ H 2 O 2 in potassium phosphate buffer) and the OD read at 460 nm. A standard curve was constructed with serial dilutions of human MPO (Sigma).
Histological examination of the small intestine
Histological examination of the small intestine was performed to assess intestinal injury and inflammation. Since no gross injury was observed in the intestine in all animals receiving 7-NI, multiple random section were removed, fixed in 10% formalin and processed for microscopic examination. In addition, random sections were taken from the liver, spleen, kidneys, heart, and lungs from 7-NI-treated animals and processed for histology.
Determination of plasma LPS levels
The plasma level of bacterial LPS was determined using a quantitative chromogenic version of the Limulus amebocyte lysate (LAL) assay (20) . The assay was performed using a LAL kit (BioWhittaker Inc., Walkerville, Md.) and the procedure described in the users' manual from the manufacturer. Plasma samples were diluted with LPS-free water at the ratio 1:9, and heated in 70°C water bath for 10 min before the assay in order to suppress the endogenous inhibitor of the LAL reaction.
Statistical analysis
One-way analysis of variance (with Bonferroni method used for the post tests) was employed to analyze the data of multiple groups. Tow-sided Student's t test was used for the comparison of any two single groups. Data are presented as mean Ϯ se. The difference between groups was considered significant when PϽ0.05.
RESULTS
Inhibition of nNOS by 7-NI results in iNOS expression and NF-B activation in small intestine
In normal rat small intestine, there is a low level of constitutive expression of iNOS, as previously reported (7, 21) (Fig. 1, upper panel) . As early as 1 day after the first injection, 7-NI treatment significantly increased both the intestinal iNOS mRNA and iNOS protein content, as revealed by RT-PCR and Western blot (Fig.  1) . The elevation in the iNOS protein content reached a peak at 4 days after 7-NI treatment, with the protein content almost fivefold of that of the controls.
Parallel to the elevation in iNOS expression, there was an up-regulation of the NF-B activity. NF-B is constitutively active at a low level in rat small intestine as previously reported (16). 7-NI treatment resulted in a significant enhancement of the intestinal NF-B activity as soon as 1 day after the drug administration (Fig. 2, upper panel) . Activation of NF-B was sustained throughout the entire period (4 days) of 7-NI treat- ment. Supershift assays show that the activated NF-B include both p65 and p50 subunits, probably as both p50-p65 heterodimers and p50-p50 homodimers, since the NF-B band was supershifted by anti-p50 mAb almost totally and by anti-p65 mAb partially (Fig. 2,  lower panel) .
PDTC suppressed 7-NI-induced NF-B activation and iNOS expression in rat small intestine
PDTC, a NF-B inhibitor, was given to the animal together with 7-NI in order to examine whether up-regulation of NF-B in the intestine is causally related to iNOS expression. EMSA showed that intestinal NF-B activity in animals treated with 7-NI plus PDTC was much lower than that in animals receiving 7-NI alone (Fig. 3, upper panel) . PDTC also prevented 7-NI-induced iNOS expression (Fig. 4, upper panel) , iNOS protein content (Fig. 3, lower  panel) , and enzyme activity (Fig. 4, lower panel) . PDTC itself showed no effect on either intestinal NF-B activity (Fig. 3, upper panel) , intestinal iNOS gene expression (Fig. 4, upper panel) , protein content (Fig. 3, lower  panel) , or enzyme activity (Fig. 4, lower panel) , compared with controls (Fig. 3, lower panel, and Fig. 4 ).
7-NI injection reduced the tissue content of IB␣ in the small intestine, which is reversed by PDTC
We examined the effect of 7-NI on the tissue content of IB␣, which binds to NF-B and prevents its nuclear translocation. As shown in Fig. 5 , animals that received 7-NI for 4 days had markedly lower intestinal IB␣, which was reversed by the treatment with PDTC together with 7-NI. No significant difference was detected between the animals treated with PDTC alone and controls.
7-NI induces a delayed neutrophil sequestration in the small intestine that is abrogated by PDTC; increase in MPO was much slower than that of NF-B and iNOS expression
To rule out the possibility that increased iNOS expression in the intestine was a result of an inflammatory response due to 7-NI administration, we examined the change of intestinal MPO activity (an index of neutrophil sequestration and inflammation) after 7-NI injection. As shown in Fig. 6 , lower panel, animals that received 7-NI for 4 days had a marked increase in intestinal MPO, which was abrogated by treatment with PDTC. No significant difference was detected between the animals treated with PDTC alone and sham controls. In contrast to intestinal NF-B and iNOS expression ( Figs. 1 and 2 ), which showed a significant elevation on the first day after 7-NI administration, the rise in MPO activity after 7-NI was much slower, showing virtually no change from baseline on the first day and a barely 20% increase on the second day (Fig. 6, upper  panel) .
No gross injury of the intestine was observed in any of the animals receiving 7-NI. Microscopic examination showed that on day 4, only 2 of 5 animals had very mild histological injury with focal loss of epithelial cells at the villous tip (not shown). Postmortem examination showed no pathology in other organs. The intestinal histology at 1 day after 7-NI is entirely unremarkable (nϭ6). There is no evidence of inflammation or neutrophil infiltration in any of the samples, suggesting that the increased MPO activity on day 4 was probably due to increased leukocyte rolling, margination, and adhesion rather than leukocyte infiltration of the tissue.
All animals tolerated 7-NI well. There were no signs of toxicity such as weight loss, diarrhea, or loss of activity for up to 4 days after 7-NI injection.
Plasma LPS levels are not elevated after 7-NI administration
LPS is a potent inducer of iNOS. It is possible that 7-NI induces an inflammatory response in the intestine that results in mucosal barrier breakdown, leading to bacterial translocation and LPS release. To rule out the possibility that the increased iNOS expression is due to bacteria/LPS entry, we examined the LPS level in the plasma in the early stage after 7-NI treatment. As shown in Fig. 7 , there is no elevation in plasma LPS after 7-NI injection compared with sham operated animals.
DISCUSSION
The physiological roles of constitutive NOS (cNOS) in the intestine have been well established. These include maintaining intestinal blood flow (3, 4), preventing leukocyte-endothelial adhesion (22) , and protection against injury (23, 7) . Our previous studies reveal nNOS to be the predominant (Ͼ90%) cNOS in the intestine (6) . The main function of nNOS in the intestine is generally believed to be mediation of the neuronal signal transmission in the NANC components of the nervous system (24) and regulating gut motility (25, 26) . Since eNOS accounts for only a very small part of intestinal NOS activity (6), it is possible that nNOS in the intestine also functions as the protective eNOS. This is suggested by our previous work showing an inverse relationship between the degree of gut injury and nNOS activity after PAF injection (7) . The present study suggests another physiological function of nNOS, i.e., to keep iNOS suppressed in the normal condition, via the production of NO.
Nitric oxide has diverse physiological functions in the body. In addition to its well-documented roles in the regulation of vasculature tone, neurotransmission, and immune self-defense against microbes and tumor cells (1, 2), a growing number of studies have recently implicated it in the regulation of gene expression, particularly the expression of some adhesion molecules (27) and iNOS (28, 29) . The present study adds one more role, i.e., gene regulation, to the vast and diverse functions of this molecule. Although there has been some evidence showing that NO from nNOS regulates iNOS expression in cultured astrocytes (29) , our study is the first to demonstrate its role in gene regulation in vivo.
Our data suggest that, in the intestine, NO produced by nNOS down-regulates iNOS via the suppression of NF-B activation. This is supported by our findings that nNOS inhibition by 7-NI induces iNOS expression and upregulates NF-B activity, and that inhibition of NF-B abolishes the effect of 7-NI. The detailed mechanism of this regulation is unclear. However, it is unlikely that the iNOS induction is a result of inflammatory response due to the injection of 7-NI. This is supported by the following data. 1) The observed activation of NF-B and iNOS expression preceded the inflammatory response (indicated by the delayed neutrophil sequestration into the intestine). 2) PDTC suppressed the 7-NI induced inflammatory response, indicating that the development of the inflammatory response is dependent on NF-B-dependent molecules such as proinflammatory cytokines and adhesion molecules. In other words, inflammation is consequent upon, but not preceding, NF-B activation. 3) There is no elevation in plasma LPS levels after 7-NI injection, indicating lack of bacteria/LPS translocation. 4) Histological examination of the intestine showed no intestinal injury on the first day after 7-NI injection. Although there was no sign of intestinal injury or inflammation before iNOS change, preliminary experiments showed that intestinal blood flow dropped to ϳ60% of baseline level on the first day (data not shown). This degree of drop in splanchnic flow is not necessarily pathological; it can be observed in physiological conditions such as strenuous exercise (30, 31) . However, the possibility exists that the decreased flow could result in change of redox status of the intestine, which may in turn affect NF-B activity. An alternative explanation is that the up-regulation of NF-B and subsequent iNOS gene expression after 7-NI injection could be a direct effect of decreased NO. A similar observation has been made in vitro in astrocyte culture. Togashi et al. demonstrated that inhibition of NO production by endogenous nNOS induces the activation of NF-B and subsequent iNOS expression in these cells (29) . It has also been demonstrated that NO regulates iNOS expression by inhibiting the binding of NF-B to DNA (32) . That iNOS expression is modulated by nNOS may be of special significance in organs such as brain and small intestine, where nNOS is the predominant NOS form (7) .
Activation of NF-B is controlled by its cytoplasmic inhibitor, IB, which binds NF-B and masks its nuclear translocation signal, thus retaining it in the cytoplasm (33, 34) . Challenging cells with cytokines or reactive oxygen radicals causes the phosphorylation-ubiquitination and subsequent degradation of IB, thus leading to the release of NF-B for its translocation to the nucleus (35) . In the present study, we showed that modulation of IB␣ is at least a part of the mechanism(s) whereby NO regulates NF-B activity and iNOS expression in rat small intestine. A similar observation has been made in endothelial cells that exogenously applied NO inhibits NF-B (p50-p65) activation, primarily through reducing the degradation or increasing the transcription of IB␣ (36) . Further, NO has been reported to inhibit NF-B-DNA binding affinity through S-nitrosylation of the cysteine 62 residue of p50 (37) .
The hypothetical model that nNOS suppresses iNOS expression through NO modulation of NF-B activation makes good teleological sense. It is generally believed that although a low level of NO is needed for maintaining physiological function and cytoprotection, a large amount of NO may be cytotoxic (38) , especially in the presence of ROS, when the toxic peroxynitrite is formed (39, 40) . Hence NO production must be placed under stringent control. Under normal conditions, iNOS (which produces massive amount of NO) is unnecessary and should be contained. The NO-mediated suppression of NF-B activity and subsequent down-regulation of the expression of iNOS and other proinflammatory cytokines would serve this purpose very well.
However, in a pathological situation such as inflammation, the demand for NO production is changed. To initiate a successive inflammatory response, the level of NO production has to be brought down first so that leukocyte-endothelial adhesion, which is repressed by NO, may take place (41, 42) . Indeed, many inflammatory mediators, such as LPS, TNF, and IFN-␥, have been found to suppress the expression (43, 44) or the activity (12, 45, 46) of cNOS. Our previous study also demonstrated that PAF, a potent inflammatory mediator in the gut, reduced intestinal nNOS activity to half of normal within 1 h (6). Such an inhibition of cNOS activity would reduce the NO-dependent suppression of NF-B, leading to NF-B-mediated transcription of proinflammatory cytokines and adhesion molecules (27, (47) (48) (49) (50) to facilitate the inflammatory response. However, after successful mobilization of leukocytes to the inflamed site, a large quantity of NO would soon be needed for the bacteriocidal action (51, 52) . Thus, iNOS would have to be 'switched on'. The above-described cNOS-dependent, NF-B-mediated regulation of iNOS expression could help to accomplish this purpose.
Our results also suggest the existence of a NOmediated negative feedback loop that may have a profound effect on the regulation of the inflammatory process, and cNOS and iNOS might 'switch' roles during inflammation in order to meet the changed need of NO production. Firstly, NO from iNOS would function to reduce the recruitment of leukocytes into the inflamed region as well as to suppress free radical production (53) . Furthermore, NO could repress NF-B-dependent transcription of iNOS and other proinflammatory cytokines, thus helping to dissipate the inflammatory response. The role of iNOS in the dissipation of inflammation is suggested by the observed iNOS-dependent inhibition of adhesion molecule expression (54) and the exaggerated tissue damage in experimental colitis in iNOS-deficient mice (55) . Eventually, as iNOS is suppressed, cNOS would resume the normal expression and activity, and normalcy would be restored.
